The thread running beneath all of this is regulatory accumulation: the quiet, procedural hardening of barriers that does not announce itself as opposition but functions as delay. FDA guidance requiring cardiac monitoring protocols for ibogaine and ibogaine-analog IND submissions — which the signal density now makes near-certain before Q1 2027 — does not kill these compounds. It extends their timelines by twelve to eighteen months and repositions the race: the analog that can demonstrate clean QTc data in Phase 1 wins not just a clinical argument but a regulatory opening. Oxa-noribogaine is the name to watch. If its Phase 1 cardiac readout is clean, the analog camp's engineering thesis validates — a solvable problem, not a fatal one. The highest trajectory available from here is not rapid approval but the disciplined accumulation of the right data by the right compound at the right moment, arriving into a regulatory window that is genuinely forming, if slowly. The stalled clock is not broken. It is being wound.
For the veterans who are not waiting — who are traveling to clinics in Mexico and Costa Rica, who are weeping in ceremony rooms because nothing else has worked, who are coming home with sleeping restored and rage dissolved and decades of dissociation finally metabolized — the regulatory clock is not abstract. Every twelve-month delay is measured in human cost: marriages that do not survive, opioids that fill the gap, lives that do not continue. The highest positive outcome for these people is not a distant approval but a near-term research pathway carve-out — the kind that a targeted NDAA amendment could create, neither full approval nor full blockade, but a protected lane in which the evidence can build inside the United States, close to home, with proper cardiac monitoring and proper care. That lane is politically available. The moral urgency is bipartisan and documented. What is forming beneath the surface of the legislative stall is the pressure required to open it.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The future does not wait for permission — it arrives through those who are ready.
82%
No psychedelic drug will be approved or rescheduled by end of 2026
MDMA (the active ingredient in ecstasy) got rejected by the FDA in 2024 and needs more data before resubmission. Psilocybin (magic mushrooms' active compound) is years away from even applying for approval. Congress hasn't passed any bills to reschedule these drugs federally. Every pathway to approval or rescheduling hits a wall before 2027.
→ FDA approval and federal rescheduling of psychedelics are both stuck in regulatory or legislative gridlock and won't happen before 2027.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
No psychedelic compound will receive FDA approval or be federally rescheduled before 2026-12-31.. MDMA NDA (Lykos/MAPS): FDA issued a Complete Response Letter in August 2024; resubmission faces supplemental data requirements and a hostile advisory committee posture. No resubmission date is confirmed. Psilocybin: no NDA filed; earliest possible approval is 2028+. Ibogaine analogs: Phase 2 stage a
79%
FDA will mandate cardiac monitoring for ibogaine drug trials by January 2027
Ibogaine, a plant medicine some people use for addiction, can affect the heart's electrical rhythm. The FDA (the US drug regulator) has seen enough published research showing this risk that it will issue formal written guidance requiring anyone testing ibogaine to monitor patients' hearts closely. This is standard FDA practice when a drug shows a consistent safety signal.
→ The FDA will formally require heart monitoring in any ibogaine study, making the drug harder and more expensive to test.
Resolves: 2027-01-15 · USA
REGULATION
the precise call ▾
FDA will issue formal written guidance requiring cardiac monitoring protocols (including QT-interval surveillance) as a prerequisite for any ibogaine or ibogaine-analog IND submission, before 2027-01-15.. Published QT-prolongation and arrhythmia data for ibogaine have reached a density that FDA's safety division treats as a compound-class signal. FDA's standard regulatory response to such signals is formal guidance or a safety communication, not case-by-case IND holds. The agency has precedent for is
72%
Ibogaine heart risk will force FDA to delay trials into 2027
Ibogaine's risk to heart rhythm is now documented clearly enough in published research that the FDA will treat it as an official safety signal. This means anyone wanting to run an ibogaine trial will face mandatory cardiac monitoring requirements, which will delay trial startup and add costs. FDA precedent shows they respond this way to cardiac risks in new brain drugs.
→ Heart-safety regulations will force ibogaine developers to add monitoring protocols, pushing trial timelines well into 2027.
Resolves: 2026-07-31 · Global
REGULATION
the precise call ▾
Ibogaine cardiac safety literature will constitute a recognized regulatory signal sufficient to require mandatory cardiac monitoring protocols in any new IND submission for ibogaine or close analogs, delaying direct ibogaine clinical development timelines materially into 2027.. Five of seven simulation agents (fda_reviewer, neuropharmacologist, journalist, dea_officer, portfolio_manager) converged on this view. Dissenting agents (veteran_advocate, maps_researcher) argued compassionate-use pressure could override safety caution; this is historically rare for cardiac signals
80%
Psychedelic biotech stocks won't recover to 2024 peaks by September 2026
Psychedelic drug companies' stock prices fell sharply from their 2024 highs and haven't bounced back. Without an actual FDA approval or a clear sign that one is coming, investors see no reason to pour money back in. The sector needs real regulatory wins to recover.
→ Psychedelic biotech stocks need an actual FDA approval or acceptance signal to recover—market sentiment and hope alone won't get them back to 2024 levels.
Resolves: 2026-09-30 · USA
MARKET
the precise call ▾
Psychedelic biotech sector aggregate market cap will not recover to 2024 highs before 2026-09-30, absent an FDA approval or clear NDA acceptance for a psychedelic compound.. All major tracked psychedelic biotech equities are trading significantly below 2024 highs with no near-term binary catalyst visible. MDMA NDA remains unresolved with supplemental data requests outstanding. Psilocybin is not at NDA stage. Institutional capital inflows are contingent on regulatory de-
78%
Psychedelic biotech stocks will stay depressed through September 2026
Multiple industry experts agree: psychedelic drug company stocks are down and won't recover until the FDA actually approves a drug or gives clear signals it will. Without real regulatory progress, the sector will languish. This prediction captures broad expert consensus on market dynamics.
→ Psychedelic biotech stocks are stuck until the FDA actually approves or greenlights a drug—market recovery depends on real regulatory action, not hope.
Resolves: 2026-09-30 · USA
MARKET
the precise call ▾
Psychedelic biotech equities will remain below 2024 high-water marks through 2026-09-30, with no sector-wide recovery absent a positive FDA binary event.. This prediction is substantively identical to prediction 1 but was generated by a consensus round rather than a single agent. Retained as a distinct entry only because it records multi-agent consensus. Four agents (portfolio_manager, journalist, fda_reviewer, dea_officer) supported; two dissented. T